GSK Denmark
在场
GSK Denmark 的所有者是 GSK.
是其中之一......
- Forbes Global 2000 (#183);
- Fortune 500 Europe (#104);
- FTSE 350;
- Global Fortune 500 (#400);
- Stoxx 600;
- TOB Iconic 10,000.
GSK 是一家在股票代码 GSK (GB) 下上市的公司。
GSK 在 20 个国家有直接业务。GSK 拥有 23家子公司，其中包括 Aiolos Bio、GSK ANZ 和 GSK APAC。
他们在：
涉及GSK的并购和融资。
- GSK has announced the acquisition of Aiolos Bio (公布2024一月12号).
- GSK has announced the acquisition of Bellus Health (公布2023四月19号).
高管
查看带有其 4 名主要高管的组织结构图
GSK Denmark 搜索最多的简介
- Dominika Wiktor-Brown, General Manager
- Hemal Malde, Finance Director
- Thy Trock Andresen, Medical Director
创建提醒
跟踪 GSK Denmark 的高管变动
药店
GSK 拥有 1,831 家竞争者，其中包括 Pfizer (美国(美洲))、Johnson & Johnson (美国(美洲)) 和 Sanofi (法国)。
Popular M&A news in 药店
- Stemtech and Seacret Direct have announced they will merge (公布2024十二月5号)..
- Recursion Pharma and Exscientia have merged (公布2024十一月27号)..
- Stemtech and Seacret Direct have announced they will merge (公布2024十一月22号)..
药店 行业的其他推荐联系人
消息
GSK Denmark 的最新新闻稿
- US FDA accepts GSK’s submission for the use of Nucala (mepolizumab) in COPD | GSK
- Blenrep shows significant overall survival benefit, reducing the risk of death by 42% in multiple myeloma at or after first relapse | GSK
- Jemperli (dostarlimab) receives US FDA Breakthrough Therapy Designation for locally advanced dMMR/MSI-H rectal cancer | GSK
- GSK’s B7-H3-targeted antibody-drug conjugate, GSK’227, receives EMA Priority Medicines (PRIME) Designation in relapsed extensive-stage small-cell lung cancer | GSK
- GSK announces FIRST trial met its primary endpoint of progression free survival in first line advanced ovarian cancer | GSK
- Jemperli (dostarlimab) plus chemotherapy receives positive CHMP opinion to expand approval to all adult patients with primary advanced or recurrent endometrial cancer | GSK
- GSK’s fully liquid Menveo meningococcal vaccine approved by European Commission | GSK
- GSK and Zhifei revise and extend strategic vaccine collaboration in China | GSK
- First single-dose medicine for P. vivax malaria prequalified by WHO and included in WHO Guidelines | GSK
- Arexvy approval expanded to adults aged 50-59 at increased risk of severe RSV disease in Japan | GSK
- View more press releases Close
通过电子邮件
